Financial Performance
5Y price score: 93
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 457.5%
US$ Per
Share
By default your notes are visible only to you.
353.9
52-week range
556.5
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
6.2 %
Dividend Yield TTM
0.7 %
Market cap $
$ 89,142
Price / Earnings TTM
13.8
Price / Book TTM
(14)
PEG TTM
0.5
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
6.2 %
74.4 %
457.5 %
Free cash flow per share growth
54.8 %
80 %
503.1 %
Earnings per share growth
29 %
159.7 %
468.7 %
Founded: 1,989
Employees: 226,000
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 24, 2026)
1) Strategy & Leadership - HCA Healthcare emphasizes the importance of health insurance coverage for access and affordability in healthcare. - The company faced challenges due to the expiration of enhanced premium tax credits, leading to a significant increase in uninsured patients. - HCA's leadership remains committed to delivering high-quality care despite these challenges, with a focus on operational efficiency and financial resiliency.
2) Financial & Segment Results - Q2 2026 saw an 11% growth in diluted earnings per share year-over-year. - Adjusted admissions from health insurance exchanges declined by 15%, with a 1-for-1 migration to uninsured status. - Same facility volume metrics showed: - Admissions up 2.5% - Equivalent admissions up 2.7% - Inpatient surgeries down 2.3% - Outpatient surgeries down 3.4% - Emergency room visits up 3.6% - Adjusted EBITDA was impacted by approximately $400 million due to the unfavorable payer mix shift.
3) Problems / Headwinds - The expiration of enhanced premium tax credits has led to a substantial increase in uninsured patients, creating financial pressure. - The company experienced a significant decline in patients covered by health insurance exchanges, which contributed to the overall decline in insured volumes. - The payer mix shift has negatively affected adjusted EBITDA, with expectations of continued challenges in the second half of 2026.
4) Operational or Product Plans - HCA plans to invest over $7 billion in capital expenditures over the next three years to enhance capacity and service offerings. - The company is focused on expanding its outpatient network, with plans for an additional 250 to 300 outpatient facilities. - HCA is advancing its financial resiliency program to improve operational efficiency and cost management.
5) Guidance & Outlook / Investor Angle - Revised guidance for 2026 includes: - Revenue between $77 billion and $79.5 billion - Adjusted EBITDA between $15.4 billion and $16.1 billion - Net income attributable to HCA between $6.3 billion and $6.7 billion - Diluted earnings per share between $28.70 and $30.50 - The company anticipates a continued headwind from the payer mix shift, with an estimated negative impact on adjusted EBITDA of $1 billion to $1.2 billion from health insurance exchanges.
Bottom line: HCA Healthcare is navigating significant headwinds from a shift in payer mix and the loss of enhanced premium tax credits, impacting its financial outlook. However, the company remains committed to investing in growth and operational efficiency, positioning itself for long-term resilience and shareholder value.
Annual Reports, Presentations And IR Contacts
Go to the websiteHCA Healthcare, Inc. — Financial Overview, Stock Price, Market Cap
HCA Healthcare, Inc. is a company. Founded in 1989. As of August 14, 2026, the company's market capitalization is $89142328433 with a current stock price of $411.74.